Mineralocorticoid Receptor Signaling in Peripheral Blood Cells in Patients with Multiple Sclerosis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168883 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Franziska Küstermann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Neurologie, University of Leipzig, 04103 Leipzig, Germany. Hauptthemen laut MEDLINE: Receptors, Mineralocorticoid, Multiple Sclerosis, Leukocytes, Mononuclear, Signal Transduction. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Leipzig’s Open Access Publishing Fund, German Research Foundation (DFG).
Abstract (Originalsprache)
Multiple sclerosis (MS) is associated with alterations in neuroendocrine function, primarily the hypothalamic–pituitary–adrenal axis, including lower expression of the glucocorticoid receptor (GR) and its target genes in peripheral blood mononuclear cells (PBMC) or full blood. We previously found reduced mineralocorticoid receptor (MR) expression in MS patients’ peripheral blood. MS is being treated with a widening variety of disease-modifying treatments (DMT), some of which have similar efficacy but different mechanisms of action; body-fluid biomarkers to support the choice of the optimal initial DMT and/or to indicate an unsatisfactory response before clinical activity are unavailable. Using cell culture of volunteers’ PBMCs and subsequent gene expression analysis (microarray and qPCR validation), we identified the mRNA expression of OTUD1 to represent MR signaling. The MR and MR target gene expression levels were then measured in full blood samples. In 119 MS (or CIS) patients, the expression of both MR and OTUD1 was lower than in 42 controls. The expression pattern was related to treatment, with the MR expression being particularly low in patients treated with fingolimod. While MR signaling may be involved in the therapeutic effects of some disease-modifying treatments, MR and OTUD1 expression can complement the neuroendocrine assessment of MS disease course. If confirmed, such assessment may support clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Klinik und Poliklinik für Neurologie, University of Leipzig, 04103 Leipzig, Germany.
- Faculty of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany.
ORCID-Profile: Florian Then Bergh
Förderung
- University of Leipzig’s Open Access Publishing Fund
- German Research Foundation (DFG)
Zitieren
APA
Küstermann, F., Busse, K., Orthgieß, J., Stoppe, M., Haars, S., & Then Bergh, F. (2024). Mineralocorticoid Receptor Signaling in Peripheral Blood Cells in Patients with Multiple Sclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168883
Vancouver
Küstermann F, Busse K, Orthgieß J, Stoppe M, Haars S, Then Bergh F. Mineralocorticoid Receptor Signaling in Peripheral Blood Cells in Patients with Multiple Sclerosis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168883
BibTeX
@article{Kstermann2024,
author = {Küstermann, Franziska and Busse, Kathy and Orthgieß, Johannes and Stoppe, Muriel and Haars, Sarah and Then Bergh, Florian},
title = {Mineralocorticoid Receptor Signaling in Peripheral Blood Cells in Patients with Multiple Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168883}
}
EUVIMED